Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2024 Rev YoY: N/A EPS YoY: -49.5% Move: -1.96%

Anixa Biosciences Inc

ANIX

$2.50 -1.96%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q2 2024

Published: Jun 4, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ANIX

Reported

Report Date

Jun 4, 2024

Quarter Q2 2024

Revenue

N/A

YoY: N/A

EPS

-0.10

YoY: -49.5%

Market Move

-1.96%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

EPS of $-0.10 decreased by 49.5% from previous year
Net income of -3.14M
"N/A" - N/A

ANIX

Company ANIX

Period Q2 2024

Currency USD

Report Type Quarterly Earnings

Generated Mar 30, 2026

Swipe to view all report sections

Executive Summary

Anixa Biosciences posted a QQ2 2024 operating profile that remains early-stage and R&D-intensive, with no reported revenue and a net loss of $3.14 million. The quarter reflects continued investment in core programs (R&D of $1.646 million and G&A of $1.821 million), culminating in an EBITDA of −$3.467 million and an EPS of −$0.098. The company carries a meaningful cash and short-term investment balance that provides runway to advance pipeline programs, but operating cash burn remains a key near-term constraint absent meaningful partnering or data catalysts. Cash and investments total approximately $23.24 million, supporting liquidity into mid-term horizons, though the business remains dependent on non-operating inflows (financing, collaborations, or licensing deals) to fund ongoing development.

Key Performance Indicators

Operating Income

Decreasing

-3.47M

QoQ: 3.93% | YoY: -35.43%

Net Income

Decreasing

-3.14M

QoQ: 3.56% | YoY: -54.25%

EPS

Decreasing

-0.10

QoQ: 1.60% | YoY: -49.54%

Revenue Trend

Margin Analysis

Financial Highlights

- Revenue: Not reported for QQ2 2024 in the provided data. - Gross Profit: −$12,000; Gross Margin not meaningful without revenue. YoY gross profit change: −124.49%; QoQ: +7.69%. - Operating Income: −$3.467 million; YoY: −35.43%; QoQ: +3.93%. - Net Income: −$3.139 million; YoY: −54.25%; QoQ: +3.56%. - EPS (diluted): −$0.0984; YoY: −49.54%; QoQ: +1.60%. - EBITDA: −$3.467 million. - Free Cash Flow: −$1.456 million. - Cash, Cash Equivalents: $0.995 million; Short-term investments: $22.244 million; Total cash & investments: $23.239 million. - Total Assets: $24.355 million; Total Liabilities: $1.774 million; Total Stockholders’ Equity: $23.623 million; Retained earnings notably negative at −$234.59 million. - Current Ratio: 14.40; Quick Ratio: 14.40; Cash Ratio: 0.592. - Weighted average shares: 31.914 million; EPS diluted: −$0.098. - Price/Earnings (trailing): negative; Price/Book: ~4.01; Enterprise Value Multiple: ~−27.10 (all data per QQ2 2024 filing).

Income Statement

Metric	Value	YoY Change	QoQ Change
Gross Profit	-12.00K	-124.49%	7.69%
Operating Income	-3.47M	-35.43%	3.93%
Net Income	-3.14M	-54.25%	3.56%
EPS	-0.10	-49.54%	1.60%

Key Financial Ratios

Return on Assets

Weak

-0.13%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.13%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

14.40

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.01

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-7.55x

Negative earnings make P/E ratio not meaningful

Price to Book

Premium

4.01x

Trading at premium to book value, reflects strong intangibles or growth

Historical Earnings Comparison

Period	EPS ($)	YoY Growth	Report
Q2 2025	-0.09	+0.0%	View
Q1 2025	-0.10	+0.0%	View
Q4 2024	0.30	+0.0%	View
Q3 2024	-0.10	+0.0%	View
Q2 2024	-0.10	+0.0%	View

ANIX

Anixa Biosciences Inc

Q2 2025 Report

Anixa Biosciences Inc (ANIX) QQ2 2025 Earnings Analysis: R&D-Intensive Path Toward Oncology and Infectious Disease Programs with Liquidity Backstop...

Read full report

ANIX

Anixa Biosciences Inc

Q1 2025 Report

Anixa Biosciences Inc (ANIX) QQ1 2025 Financial Analysis: Early-stage biotech burn with improving liquidity and a development-driven outlook...

Read full report

ANIX

Anixa Biosciences Inc

Q4 2024 Report

Anixa Biosciences Inc (ANIX) QQ4 2024 Earnings Analysis – R&D-Driven Bleed with Liquidity Backstop in Healthcare/Biotechnology...

Read full report

ANIX

Anixa Biosciences Inc

Q3 2024 Report

Anixa Biosciences Inc (ANIX) QQ3 2024 Earnings Review: Narrowing Losses Amid Robust Liquidity and Early-Stage Pipeline Potential...

Read full report

Anixa Biosciences Inc (ANIX) Q2 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More ANIX Quarterly Reports

ANIX

ANIX

ANIX

ANIX

Q2 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

ANIX Full Profile

ANIX Financial Statements

Earnings Calendar